|
|   |
AUTHOR INFORMATION
| Section 1 of 10  |
|
| Author: Burke A Cunha, MD, MACP, Professor of Medicine, State University of New York at Stony Brook School of Medicine; Chief, Infectious Disease Division, Winthrop-University Hospital |
| Burke A Cunha, MD, MACP, is a member of the following medical societies:
American College of Chest Physicians,
American College of Physicians, and
Infectious Diseases Society of America |
| Editor(s): Charles S Levy, MD, Associate Professor, Department of Medicine, Section of Infectious Disease, George Washington University School of Medicine; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine;
Ronald A Greenfield, MD, Chief, Professor, Department of Internal Medicine, Section of Infectious Disease, University of Oklahoma College of Medicine;
Eleftherios Mylonakis, MD, PhD, Assistant Professor of Medicine, Harvard Medical School, Clinical Assistant in Medicine, Division of Infectious Disease, Massachusetts General Hospital;
and Michael E Zevitz, MD, Assistant Professor of Medicine, Finch University of the Health Sciences, The Chicago Medical School; Consulting Staff, Private Practice |
Disclosure
|   |
INTRODUCTION
| Section 2 of 10  |
|
Background: Stenotrophomonas (Pseudomonas) maltophilia is an aerobic gram-negative bacillus that is an infrequent pathogen in humans and is found in a variety of aquatic environments. S maltophilia is an organism of low virulence and is a frequent colonizer of fluids used in the hospital setting, ie, irrigation solutions and intravenous (IV) fluids, and of patient secretions, ie, respiratory secretions, urine, or wound exudates. S maltophilia usually must bypass normal host defenses to cause human infection. For example, if fluid in an irrigation solution becomes colonized with this organism, irrigating an open wound can cause colonization or infection of the wound. S maltophilia usually is not capable of causing disease in healthy hosts without the assistance of invasive medical devices that bypass normal host defenses. Pathophysiology: S maltophilia has few pathogenic mechanisms and, for this reason, predominantly results in colonization rather than infection. If infection does occur, invasive medical devices usually are the vehicles by which the organism bypasses normal host defenses. Otherwise, the pathophysiology of this nonfermentative aerobic gram-negative bacillus is not different from other nonfermentative aerobic organisms. Frequency:
- Internationally: In the ambulatory setting, S maltophilia is a frequent colonizer in the respiratory tract in patients with cystic fibrosis.
Mortality/Morbidity: Mortality and morbidity relate to the inoculum of S maltophilia that is able to bypass normal host defense mechanisms.
- If an intravenous infusion contains large numbers of S maltophilia, then direct injection into the bloodstream may result in the signs and symptoms associated with gram-negative bacteremia.
- Similarly, in the urinary tract, if urological irrigation fluids that contain large numbers of S maltophilia are used during an invasive urological procedure, eg, cystoscopy, then gram-negative bacteremia may occur with its attendant mortality and morbidity, which are dependent on host factors.
|   |
CLINICAL
| Section 3 of 10  |
|
History: - Because S maltophilia infections are extremely uncommon, no specific patient history suggests its presence other than contact with other colonized individuals.
- Obtaining a history of the use of irrigant solutions that could potentially contain S maltophilia is important in an epidemiological setting rather than in a clinical setting.
Physical: Signs and symptoms are related to the organ system involved. Causes: - S maltophilia is a nonfermentative aerobic gram-negative bacillus formerly classified as Pseudomonas. Unlike Pseudomonas aeruginosa, S maltophilia is an organism of low virulence with limited ability to cause infection in humans.
- S maltophilia is a water organism, and it survives and multiplies in aqueous environments, particularly respiratory secretions, urine, IV fluids, and irrigant solutions.
- S maltophilia may persist in an aquatic environment for extended periods.
- Sources of S maltophilia colonization include the following:
- Personnel
- Hands
- Antiseptic soaps
- Hand lotion
- Respiratory equipment and/or fluids
- Ultrasonic nebulizers
- Inhalation medications
- Respirator tubing condensate
- IV lines and/or fluids
- IV solutions
- Central venous catheters
- Pressure monitoring devices - Pressure transducer fluids
- Urine and/or fluids
- Indwelling Foley catheters
- Urometers
- Irrigation solutions
|   |
DIFFERENTIALS
| Section 4 of 10  |
|
Other Problems to be Considered:
The main clinical problem presented by S maltophilia is not recognizing its significance in the clinical context. The recovery of S maltophilia from respiratory secretions or from the urine of catheterized patients should be regarded as colonization until proven otherwise.
S maltophilia is a common cause of catheter-associated bacteruria in hospitalized patients. S maltophilia commonly colonizes the urine and potentially is pathogenic only in those with impaired host defenses, ie, patients with diabetes, systemic lupus erythematosus (SLE), cirrhosis, multiple myeloma, and those on steroids.
S maltophilia recovered from blood cultures may have come from contaminated IV fluids or from a distant infected source, eg, secondary bacteremia from the urinary tract in a patient who recently underwent instrumentation during a genitourinary (GU) procedure.
S maltophilia recovered from a wound with a clear or a serosanguineous discharge is of no clinical significance. If recovered from a purulent wound, S maltophilia may be the cause of the patient's wound infection.
The most common cause of confusion regarding S maltophilia is assuming that its recovery from body fluids implies a pathogenic role.
S maltophilia virtually never causes nosocomial pneumonia in patients who are ventilated and presumed to have nosocomial pneumonia because of fever, pulmonary infiltrates, and leukocytosis. The recovery of S maltophilia from respiratory secretions invariably represents colonization rather than infection, and its presence should not be addressed therapeutically.
Table 1. Hospital-Acquired S maltophilia Infections
| Infection | Predisposing Factor |
|---|
| Catheter-associated bacteriuria | Indwelling urinary catheters | | IV line infections | Central IV catheters | | Urosepsis | Urinary tract instrumentation | | Primary bacteremia | Arterial monitoring devices | | Pseudobacteremia | Contamination of blood during collection/processing of blood cultures |
|
|
Patient Education
|
|
Click here for patient education.
|
|
|
|
|
|   |
WORKUP
| Section 5 of 10  |
|
Lab Studies:
- Culture of the organism from body fluids and proper identification from the microbiology laboratory confirms the presence of S maltophilia. Usually, the presence of S maltophilia represents colonization. A potential pathogenic role must be evaluated by an infectious disease consultant. The mere recovery of a potential pathogen from any body fluid does not indicate a pathogenic role for the organism.
Histologic Findings: The histology of S maltophilia in the rare situations when it causes infection is indistinguishable from the histology of infections caused by other aerobic gram-negative bacilli.
|   |
TREATMENT
| Section 6 of 10  |
|
Medical Care: - Colonization of body fluids in hospitalized patients should be minimized if possible. Foley catheters should be used only as long as necessary and should be avoided if at all possible in immunocompromised hosts predisposed to urinary tract infections, eg, patients with diabetes, SLE, or multiple myeloma.
- Colonization of respiratory secretions in intubated patients in ICUs is the rule and is difficult to prevent.
- Patient-to-patient spread of organisms may be minimized or prevented by effective infection control measures.
Consultations: A consultation with an infectious disease specialist is essential for differentiating colonization from infection in patients with S maltophilia isolated from various body fluids.
|   |
MEDICATION
| Section 7 of 10  |
|
Because S maltophilia predominantly is a colonizer, antimicrobial treatment is unnecessary and may be potentially harmful.
As a general principle, colonization should not be treated with antimicrobial therapy.
S maltophilia, as a non–aeruginosa pseudomonad, usually is resistant to aminoglycosides, antipseudomonal penicillins, and antipseudomonal third-generation cephalosporins.
S maltophilia usually is susceptible to trimethoprim-sulfamethoxazole (TMP-SMX) or cefepime.
Drug Category: Antibiotics -- Therapy must be comprehensive and cover all likely pathogens in the context of the clinical setting. Drug Name
| Sulfamethoxazole/trimethoprim (Bactrim, Bactrim DS, Septra, Septra DS) -- Inhibits bacterial growth by inhibiting synthesis of dihydrofolic acid. Antibacterial activity includes common urinary tract pathogens, except P aeruginosa. |
|---|
| Adult Dose | 160 mg TMP 800 mg SMX PO q12h for 10-14 d |
|---|
| Pediatric Dose | <2 months: Do not administer
>2 months: 15-20 mg/kg/d (based on TMP) PO tid/qid for 14 d| Contraindications | Documented hypersensitivity; megaloblastic anemia resulting from a folate deficiency |
|---|
| Interactions | May increase PT when used with warfarin (perform coagulation tests and adjust dose accordingly); coadministration with dapsone may increase blood levels of both drugs; coadministration of diuretics increases incidence of thrombocytopenia purpura in elderly individuals; phenytoin levels may increase with coadministration; may potentiate effects of methotrexate in patients with bone marrow depression; hypoglycemic response to sulfonylureas may increase with coadministration; may increase levels of zidovudine |
|---|
| Pregnancy |
C - Safety for use during pregnancy has not been established.
|
|---|
| Precautions | Discontinue at first appearance of skin rash or sign of adverse reaction; obtain CBC counts frequently; discontinue therapy if significant hematologic changes occur; goiter, diuresis, and hypoglycemia may occur with sulfonamides; prolonged IV infusions or high doses may cause bone marrow depression (if signs occur, administer 5-15 mg/d leucovorin); caution in patients with a folate deficiency (eg, those with chronic alcoholism, elderly individuals, those receiving anticonvulsant therapy, those with a malabsorption syndrome); hemolysis may occur in patients who are G-6-PD deficient; patients with AIDS may not tolerate or respond; caution in patients with renal or hepatic impairment (perform urinalyses and renal function tests during therapy); administer fluids to prevent crystalluria and stone formation |
|---|
|
|---|
Drug Name
| Cefepime (Maxipime) -- Fourth-generation cephalosporin with good gram-negative coverage, similar to ceftazidime, but better gram-positive coverage. |
|---|
| Adult Dose | 2 g IV q12h |
|---|
| Pediatric Dose | 50 mg/kg IV q8h |
|---|
| Contraindications | Documented hypersensitivity |
|---|
| Interactions | Probenecid at a high dose decreases clearance |
|---|
| Pregnancy |
C - Safety for use during pregnancy has not been established.
|
|---|
| Precautions | Adjust dose in patients with severe renal insufficiency |
|---|
Drug Name
| Minocycline (Dynacin, Minocin) -- Treats infections caused by susceptible gram-negative and gram-positive organisms, in addition to infections caused by susceptible Chlamydia, Rickettsia, and Mycoplasma. |
|---|
| Adult Dose | 100 mg PO bid for 5-7 d |
|---|
| Pediatric Dose | <8 years: Not recommended
>8 years: 4 mg/kg PO initially, followed with 2 mg/kg q12h| Contraindications | Documented hypersensitivity; severe hepatic dysfunction |
|---|
| Interactions | Bioavailability decreases with antacids containing aluminum, calcium, magnesium, iron, or bismuth subsalicylate; can decrease effects of oral contraceptives, causing breakthrough bleeding and increased risk of pregnancy; tetracyclines can increase hypoprothrombinemic effects of anticoagulants |
|---|
| Pregnancy |
D - Unsafe in pregnancy
|
|---|
| Precautions | Photosensitivity may occur with prolonged exposure to sunlight or tanning equipment; reduce dose in renal impairment; consider drug serum level determinations in prolonged therapy; tetracycline use during tooth development (last one-half of pregnancy through age 8 y) can cause permanent discoloration of teeth; Fanconilike syndrome may occur with outdated tetracyclines; hepatitis or lupuslike syndromes may occur |
|---|
|
|---|
Drug Name
| Tigecycline (Tygacil) -- A glycylcycline antibiotic that is structurally similar to tetracycline antibiotics. Inhibits bacterial protein translation by binding to 30S ribosomal subunit, and blocks entry of amino-acyl tRNA molecules in ribosome A site. Indicated for complicated skin and skin structure infections caused by E coli, E faecalis (vancomycin-susceptible isolates only), S aureus (methicillin-susceptible and -resistant isolates), S agalactiae, S anginosus group (includes S anginosus, S intermedius, and S constellatus), S pyogenes, and B fragilis. |
|---|
| Adult Dose | Infuse each dose over 30-60 min
100 mg IV once, then 50 mg IV q12h
Severe hepatic impairment (ie, Child Pugh class C): 100 mg IV once, then 25 mg IV q12h| Pediatric Dose | <18 years: Not established
>18 years: Administer as in adults| Contraindications | Documented hypersensitivity |
|---|
| Interactions | Coadministration decreases warfarin clearance and increases warfarin Cmax and AUC (monitor aPTT and INR); coadministration of antibiotics with oral contraceptives may decrease contraceptive effect |
|---|
| Pregnancy |
D - Unsafe in pregnancy
|
|---|
| Precautions | Caution in severe hepatic impairment (reduce dose); may adversely effect tooth development; may permit clostridia overgrowth, resulting in antibiotic-associated colitis; may have adverse effects similar to tetracyclines (eg, photosensitivity, pseudotumor cerebri, pancreatitis, antianabolic action) |
|---|
|
|---|
|
|---|
Drug Name
| Meropenem (Merrem IV) -- Bactericidal broad-spectrum carbapenem antibiotic that inhibits cell-wall synthesis. Effective against most gram-positive and gram-negative bacteria.
Has slightly increased activity against gram-negative bacteria and slightly decreased activity against staphylococci and streptococci compared with imipenem.| Adult Dose | 1 g IV q8h |
|---|
| Pediatric Dose | 40 mg/kg IV q8h |
|---|
| Contraindications | Documented hypersensitivity |
|---|
| Interactions | Probenecid may inhibit renal excretion of meropenem, increasing meropenem levels |
|---|
| Pregnancy |
B - Usually safe but benefits must outweigh the risks.
|
|---|
| Precautions | Dosage adjustments (adult adjustments)
CrCl (mL/min) 50-10: 0.5-1 g q12h
CrCl <10: 0.5 g/d
HD: As for CrCl <10, with an extra 0.5 g after HD
Pseudomembranous colitis and thrombocytopenia may occur, requiring immediate discontinuation of medication |
|---|
|
|---|
|   |
FOLLOW-UP
| Section 8 of 10  |
|
Deterrence/Prevention:
- Because S maltophilia is a common nosocomial colonizer of patients and medical fluids, the recovery of S maltophilia should be considered nonpathogenic unless proven otherwise.
- If S maltophilia is recovered from several patients in the same area, sections of an ICU or ward can become the focus for further spread within the hospital setting.
- Effective infection control measures can minimize or limit the spread of this and other organisms in the ICU.
- Appropriate isolation procedures, rather than antimicrobial therapy, should be used to control the spread of S maltophilia.
- Medical personnel, including medical students, housekeeping staff, attending physicians, nursing personnel, and respiratory therapists, are potential carriers of the organism from patient to patient.
|   |
MISCELLANEOUS
| Section 9 of 10  |
|
Medical/Legal Pitfalls:
- Clinicians often make the mistake of treating S maltophilia colonization with antibiotics. Except when the pathogenic role of S maltophilia is clear (ie, IV line sepsis secondary to contaminating infusions, colonization related to IV monitoring devices, urological instrumentation resulting in colonization), the mere presence of S maltophilia should not prompt treatment because it usually implies colonization rather than infection.
- The most common clinical pitfall with S maltophilia colonization is to treat it when the organism is recovered from urine. S maltophilia bacteriuria ordinarily should not be treated. In a patient with an indwelling Foley catheter, S maltophilia may be accompanied by pyuria, which represents colonization rather than infection unless recent antecedent urological instrumentation has been performed.
- The most common clinical error with S maltophilia colonization involves treating patients on respirators in ICUs because S maltophilia was recovered from their respiratory secretions.
- Because S maltophilia does not cause pneumonia, colonization should not be treated in patients who are ventilated, even if they have fever, pulmonary infiltrates, and leukocytosis.
- The needless and inappropriate treatment of S maltophilia with antibiotics may predispose patients to adverse drug effects, eg, drug fever or drug rash secondary to the sulfisoxazole component of TMP-SMX.
- The treatment of S maltophilia colonization also may predispose patients to fungal colonization or infection because of the selective pressures on the microbial milieu in the ICU.
|   |
BIBLIOGRAPHY
| Section 10 of 10 |
|
-
Alonso A, Martinez JL: Multiple antibiotic resistance in Stenotrophomonas maltophilia. Antimicrob Agents Chemother 1997 May; 41(5): 1140-2[Medline].
-
Berbari N, Johnson DH, Cunha BA: Xanthomonas maltophilia peritonitis in a patient undergoing peritoneal dialysis. Heart Lung 1993 May-Jun; 22(3): 282-3[Medline].
-
Burdge DR, Noble MA, Campbell ME: Xanthomonas maltophilia misidentified as Pseudomonas cepacia in cultures of sputum from patients with cystic fibrosis: a diagnostic pitfall with major clinical implications. Clin Infect Dis 1995 Feb; 20(2): 445-8[Medline].
-
Cunha BA: Pseudoinfections and pseudo-outbreaks. In: Mayhall G, ed. Hospital Epidemiology and Infection Control. 2nd ed. Philadelphia, Pa: Lippencott Williams and Wilkins; 1999: 121-30.
-
Cunha BA, Klein NC: Pseudoinfections: A review. Infect Dis Clin Pract 1995; 4: 95-103.
-
Cunha BA: Infections caused by non-fermentative aerobic gram-negative bacilli in the Critical Care Unit. Antibiotics for Clinicians 2000; 4: 11-6.
-
Cunha BA: Antibiotic Essentials. 5th ed. Royal Oak, Mich: Physicians Press; 2006.
-
Denton M: Stenotrophomonas maltophilia: An emerging problem in cystic fibrosis patients. Rev Med Microbiol 1997; 8: 15-9.
-
Denton M, Kerr KG: Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev 1998 Jan; 11(1): 57-80[Medline].
-
Elting LS, Bodey GP: Septicemia due to Xanthomonas species and non-aeruginosa Pseudomonas species: increasing incidence of catheter-related infections. Medicine (Baltimore) 1990 Sep; 69(5): 296-306[Medline].
-
Elting LS, Khardori N, Bodey GP: Nosocomial infection caused by Xanthomonas maltophilia: a case-control study of predisposing factors. Infect Control Hosp Epidemiol 1990 Mar; 11(3): 134-8[Medline].
-
Fang FC, Madinger NE: Resistant nosocomial gram-negative bacillary pathogens: Acinetobacter baumannii, Xanthomonas maltophilia, and Pseudomonas cepacia. Curr Clin Top Infect Dis 1996; 16: 52-83[Medline].
-
Fujita J, Yamadori I, Xu G: Clinical features of Stenotrophomonas maltophilia pneumonia in immunocompromised patients. Respir Med 1996 Jan; 90(1): 35-8[Medline].
-
Garcia-Rodriguez JA, Garcia Sanchez JE, Munoz Bellido JL: In-vitro activity of meropenem, a new carbapenem, against imipenem- resistant Pseudomonas aeruginosa and Xanthomonas maltophilia. J Chemother 1991 Jun; 3(3): 143-6[Medline].
-
Garrison MW, Anderson DE, Campbell DM: Stenotrophomonas maltophilia: emergence of multidrug-resistant strains during therapy and in an in vitro pharmacodynamic chamber model. Antimicrob Agents Chemother 1996 Dec; 40(12): 2859-64[Medline].
-
Gilardi GL: Pseudomonas maltophilia infections in man. Am J Clin Pathol 1969 Jan; 51(1): 58-61[Medline].
-
Gilardi GL: Characterization of nonfermentative nonfastidious gram negative bacteria encountered in medical bacteriology. J Appl Bacteriol 1971 Sep; 34(3): 623-44[Medline].
-
Gilardi GL: Infrequently encountered Pseudomonas species causing infection in humans. Ann Intern Med 1972 Aug; 77(2): 211-5[Medline].
-
Khardori N, Elting L, Wong E: Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer. Rev Infect Dis 1990 Nov-Dec; 12(6): 997-1003[Medline].
-
Khardori N, Reuben A, Rosenbaum B: In vitro susceptibility of Xanthomonas (Pseudomonas) maltophilia to newer antimicrobial agents. Antimicrob Agents Chemother 1990 Aug; 34(8): 1609-10[Medline].
-
Krcmery V, Antal M, Langsadl L: Transferable amikacin resistance in Pseudomonas maltophilia and Acinetobacter calcoaceticus. Infection 1985 Mar-Apr; 13(2): 89-90[Medline].
-
Matsuyama JR, Beail B, Wallis C: Susceptibility of Xanthomonas maltophilia and amikacin-resistant gram- negative bacteria to newer antimicrobials. Clin Pharm 1991 Jul; 10(7): 544-8[Medline].
-
Morrison AJ, Hoffmann KK, Wenzel RP: Associated mortality and clinical characteristics of nosocomial Pseudomonas maltophilia in a university hospital. J Clin Microbiol 1986 Jul; 24(1): 52-5[Medline].
-
Semel JD, Trenholme GM, Harris AA: Pseudomonas maltophilia pseudosepticemia. Am J Med 1978 Mar; 64(3): 403-6[Medline].
-
Steere AC, Tenney JH, Mackel DC: Pseudomonas species bacteremia caused by contaminated normal human serum albumin. J Infect Dis 1977 May; 135(5): 729-35[Medline].
-
Sutter VL: Identification of Pseudomonas species isolated from hospital environment and human sources. Appl Microbiol 1968 Oct; 16(10): 1532-8[Medline].
-
Villarino ME, Stevens LE, Schable B: Risk factors for epidemic Xanthomonas maltophilia infection/colonization in intensive care unit patients. Infect Control Hosp Epidemiol 1992 Apr; 13(4): 201-6[Medline].
-
Wilsher ML, Kolbe J, Morris AJ: Nosocomial acquisition of Burkholderia gladioli in patients with cystic fibrosis. Am J Respir Crit Care Med 1997 Apr; 155(4): 1436-40[Medline].
-
Wishart MM, Riley TV: Infection with Pseudomonas maltophilia hospital outbreak due to contaminated disinfectant. Med J Aust 1976 Nov 6; 2(19): 710-2[Medline].
-
Yu VL, Rumans LW, Wing EJ: Pseudomonas maltophilia causing heroin-associated infective endocarditis. Arch Intern Med 1978 Nov; 138(11): 1667-71[Medline].
Stenotrophomonas Maltophilia excerpt |